Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis.

Jawhar M, Döhner K, Kreil S, Schwaab J, Shoumariyeh K, Meggendorfer M, Span LLF, Fuhrmann S, Naumann N, Horny HP, Sotlar K, Kubuschok B, von Bubnoff N, Spiekermann K, Heuser M, Metzgeroth G, Fabarius A, Klein S, Hofmann WK, Kluin-Nelemans HC, Haferlach T, Döhner H, Cross NCP, Sperr WR, Valent P, Reiter A.

Leukemia. 2019 May;33(5):1124-1134. doi: 10.1038/s41375-018-0346-z. Epub 2019 Jan 11.

PMID:
30635631
2.
3.

Autoantibodies against lamin C, NA14 and CK15 in primary vasculitides or autoimmune diseases with secondary vasculitis.

Kubuschok B, Preuss KD, Baier-Thoenes K, Regitz E, Thurner L, Assmann G, Pfreundschuh M.

Clin Exp Rheumatol. 2016 May-Jun;34(3 Suppl 97):S60-9. Epub 2016 May 19.

PMID:
27214601
4.

The molecular basis for development of proinflammatory autoantibodies to progranulin.

Thurner L, Fadle N, Regitz E, Kemele M, Klemm P, Zaks M, Stöger E, Bette B, Carbon G, Zimmer V, Assmann G, Murawski N, Kubuschok B, Held G, Preuss KD, Pfreundschuh M.

J Autoimmun. 2015 Jul;61:17-28. doi: 10.1016/j.jaut.2015.05.002. Epub 2015 May 23.

PMID:
26005049
5.

Sumoylated HSP90 is a dominantly inherited plasma cell dyscrasias risk factor.

Preuss KD, Pfreundschuh M, Weigert M, Fadle N, Regitz E, Kubuschok B.

J Clin Invest. 2015 May;125(5):2179. doi: 10.1172/JCI82091. Epub 2015 May 1. No abstract available.

6.

CD4⁺ T cells in chronic autoantigenic stimulation in MGUS, multiple myeloma and Waldenström's macroglobulinemia.

Neumann F, Pfreundschuh M, Preuss KD, Schormann C, Zwick C, Murawski N, Kubuschok B.

Int J Cancer. 2015 Sep 1;137(5):1076-84. doi: 10.1002/ijc.29478. Epub 2015 Feb 26.

7.

Management of diffuse large B-cell lymphoma (DLBCL).

Kubuschok B, Held G, Pfreundschuh M.

Cancer Treat Res. 2015;165:271-88. doi: 10.1007/978-3-319-13150-4_11. Review.

PMID:
25655614
8.

Sumoylated HSP90 is a dominantly inherited plasma cell dyscrasias risk factor.

Preuss KD, Pfreundschuh M, Weigert M, Fadle N, Regitz E, Kubuschok B.

J Clin Invest. 2015 Jan;125(1):316-23. doi: 10.1172/JCI76802. Epub 2014 Dec 8. Erratum in: J Clin Invest. 2015 May;125(5):2179. Weigert, Martin [Added].

9.

EBV-transformed lymphoblastoid cell lines as vaccines against cancer testis antigen-positive tumors.

Neumann F, Kaddu-Mulindwa D, Widmann T, Preuss KD, Held G, Zwick C, Roemer K, Pfreundschuh M, Kubuschok B.

Cancer Immunol Immunother. 2013 Jul;62(7):1211-22. doi: 10.1007/s00262-013-1412-z. Epub 2013 Apr 26.

PMID:
23619976
10.

Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia.

Pfeifer H, Wassmann B, Bethge W, Dengler J, Bornhäuser M, Stadler M, Beelen D, Vucinic V, Burmeister T, Stelljes M, Faul C, Dreger P, Kiani A, Schäfer-Eckart K, Schwerdtfeger R, Lange E, Kubuschok B, Horst HA, Gramatzki M, Brück P, Serve H, Hoelzer D, Gökbuget N, Ottmann OG; GMALL Study Group.

Leukemia. 2013 Jun;27(6):1254-62. doi: 10.1038/leu.2012.352. Epub 2012 Dec 5.

PMID:
23212150
11.

Mutated Ras-transfected, EBV-transformed lymphoblastoid cell lines as a model tumor vaccine for boosting T-cell responses against pancreatic cancer: a pilot trial.

Kubuschok B, Pfreundschuh M, Breit R, Hartmann F, Sester M, Gärtner B, König J, Murawski N, Held G, Zwick C, Neumann F.

Hum Gene Ther. 2012 Dec;23(12):1224-36. doi: 10.1089/hum.2011.153. Epub 2012 Oct 31.

PMID:
22966960
12.

A peptide epitope derived from the cancer testis antigen HOM-MEL-40/SSX2 capable of inducing CD4⁺ and CD8⁺ T-cell as well as B-cell responses.

Neumann F, Kubuschok B, Ertan K, Schormann C, Stevanovic S, Preuss KD, Schmidt W, Pfreundschuh M.

Cancer Immunol Immunother. 2011 Sep;60(9):1333-46. doi: 10.1007/s00262-011-1030-6. Epub 2011 Jun 1.

PMID:
21630107
13.

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad antibody responses in humans, a RAYS-based analysis.

Mischo A, Bubel N, Cebon JS, Samaras P, Petrausch U, Stenner-Liewen F, Schaefer NG, Kubuschok B, Renner C, Wadle A.

Int J Oncol. 2011 Jul;39(1):287-94. doi: 10.3892/ijo.2011.1032. Epub 2011 May 6.

PMID:
21573493
14.

Cryptic epitopes induce high-titer humoral immune response in patients with cancer.

Fischer E, Kobold S, Kleber S, Kubuschok B, Braziulis E, Knuth A, Renner C, Wadle A.

J Immunol. 2010 Sep 1;185(5):3095-102. doi: 10.4049/jimmunol.0902166. Epub 2010 Jul 26.

15.

Analysis of the antibody repertoire of patients with mantle cell lymphoma directed against mantle cell lymphoma-associated antigens.

Zwick C, Preuss KD, Kubuschok B, Held G, Ahlgrimm M, Bittenbring J, Schubert J, Neumann F, Pfreundschuh M.

Ann Hematol. 2009 Oct;88(10):999-1003. doi: 10.1007/s00277-009-0711-0. Epub 2009 Feb 24.

PMID:
19238384
16.

Spontaneous high-titered IgG antibody responses against BCL-2 in patients with aggressive lymphomas.

Zwick C, Held G, Hammermeister V, Alahmad A, Kubuschok B, Bittenbring J, Ahlgrimm M, Neumann F, Preuss KD, Pfreundschuh M.

J Cancer Res Clin Oncol. 2009 Sep;135(9):1207-13. doi: 10.1007/s00432-009-0561-0. Epub 2009 Feb 21.

PMID:
19234720
17.
18.

Cross-presentation of HLA class I epitopes from influenza matrix protein produced in Saccharomyces cerevisiae.

Wadle A, Held G, Neumann F, Kleber S, Wuellner B, Asemissen AM, Kubuschok B, Scheibenbogen C, Breinig T, Meyerhans A, Renner C.

Vaccine. 2006 Sep 11;24(37-39):6272-81. Epub 2006 Jun 14.

PMID:
16860448
19.

Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer.

Kubuschok B, Neumann F, Breit R, Sester M, Schormann C, Wagner C, Sester U, Hartmann F, Wagner M, Remberger K, Schilling M, Pfreundschuh M.

Clin Cancer Res. 2006 Feb 15;12(4):1365-72.

20.

Serological immune response to cancer testis antigens in patients with pancreatic cancer.

Wadle A, Kubuschok B, Imig J, Wuellner B, Wittig C, Zwick C, Mischo A, Waetzig K, Romeike BF, Lindemann W, Schilling M, Pfreundschuh M, Renner C.

Int J Cancer. 2006 Jul 1;119(1):117-25.

21.

Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer.

Mischo A, Kubuschok B, Ertan K, Preuss KD, Romeike B, Regitz E, Schormann C, de Bruijn D, Wadle A, Neumann F, Schmidt W, Renner C, Pfreundschuh M.

Int J Cancer. 2006 Feb 1;118(3):696-703.

22.

Identification of an epitope derived from the cancer testis antigen HOM-TES-14/SCP1 and presented by dendritic cells to circulating CD4+ T cells.

Neumann F, Wagner C, Preuss KD, Kubuschok B, Schormann C, Stevanovic S, Pfreundschuh M.

Blood. 2005 Nov 1;106(9):3105-13. Epub 2005 Jul 19.

23.

Serological identification of breast cancer-related antigens from a Saccharomyces cerevisiae surface display library.

Wadle A, Mischo A, Imig J, Wüllner B, Hensel D, Wätzig K, Neumann F, Kubuschok B, Schmidt W, Old LJ, Pfreundschuh M, Renner C.

Int J Cancer. 2005 Oct 20;117(1):104-13.

24.

Rapid identification of preformed alloreactive T cells for use in a clinical setting.

Sester U, Thijssen S, van Bentum K, Neumann F, Kubuschok B, Sester M, Köhler H.

Transplantation. 2004 Aug 27;78(4):607-14.

PMID:
15446322
25.

Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2.

Neumann F, Wagner C, Stevanovic S, Kubuschok B, Schormann C, Mischo A, Ertan K, Schmidt W, Pfreundschuh M.

Int J Cancer. 2004 Nov 20;112(4):661-8.

26.

Expression of cancer testis antigens in pancreatic carcinoma cell lines, pancreatic adenocarcinoma and chronic pancreatitis.

Kubuschok B, Xie X, Jesnowski R, Preuss KD, Romeike BF, Neumann F, Regitz E, Pistorius G, Schilling M, Scheunemann P, Izbicki JR, Löhr JM, Pfreundschuh M.

Int J Cancer. 2004 Apr 20;109(4):568-75.

27.

Identification of an antigenic peptide derived from the cancer-testis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypes.

Neumann F, Wagner C, Kubuschok B, Stevanovic S, Rammensee HG, Pfreundschuh M.

Cancer Immunol Immunother. 2004 Jul;53(7):589-99. Epub 2004 Jan 23.

PMID:
14745515
28.

p-[123I]iodo-L-phenylalanine for detection of pancreatic cancer: basic investigations of the uptake characteristics in primary human pancreatic tumour cells and evaluation in in vivo models of human pancreatic adenocarcinoma.

Samnick S, Romeike BF, Kubuschok B, Hellwig D, Amon M, Feiden W, Menger MD, Kirsch CM.

Eur J Nucl Med Mol Imaging. 2004 Apr;31(4):532-41. Epub 2004 Jan 14.

PMID:
14722685
29.

Identification of an HLA-A*02 restricted immunogenic peptide derived from the cancer testis antigen HOM-MEL-40/SSX2.

Wagner C, Neumann F, Kubuschok B, Regitz E, Mischo A, Stevanovic S, Friedrich M, Schmidt W, Rammensee HG, Pfreundschuh M.

Cancer Immun. 2003 Dec 17;3:18.

30.

[Simultaneous immunocytochemical detection of tumor cells in lymph nodes and in bone marrow of patients with resectable bronchial carcinomas].

Passlick B, Pantel K, Kubuschok B, Izbicki JR, Thetter O.

Langenbecks Arch Chir Suppl Kongressbd. 1998;115(Suppl I):21-4. German.

PMID:
14518204
32.

Expression of cancer-testis genes in human hepatocellular carcinomas.

Luo G, Huang S, Xie X, Stockert E, Chen YT, Kubuschok B, Pfreundschuh M.

Cancer Immun. 2002 Sep 19;2:11.

33.

Use of spontaneous Epstein-Barr virus-lymphoblastoid cell lines genetically modified to express tumor antigen as cancer vaccines: mutated p21 ras oncogene in pancreatic carcinoma as a model.

Kubuschok B, Schmits R, Hartmann F, Cochlovius C, Breit R, König J, Pistorius G, Schilling M, Renner C, Pfreundschuh M.

Hum Gene Ther. 2002 May 1;13(7):815-27.

PMID:
11975848
34.

Sustained high frequencies of specific CD4 T cells restricted to a single persistent virus.

Sester M, Sester U, Gärtner B, Kubuschok B, Girndt M, Meyerhans A, Köhler H.

J Virol. 2002 Apr;76(8):3748-55.

35.

Analysis of the B cell repertoire against autoantigens in patients with giant cell arteritis and polymyalgia rheumatica.

Schmits R, Kubuschok B, Schuster S, Preuss KD, Pfreundschuh M.

Clin Exp Immunol. 2002 Feb;127(2):379-85.

36.

Clinical approaches to vaccination in oncology.

Renner C, Kubuschok B, Trümper L, Pfreundschuh M.

Ann Hematol. 2001 May;80(5):255-66. Review.

PMID:
11446727
37.

Gene-modified spontaneous Epstein-Barr virus-transformed lymphoblastoid cell lines as autologous cancer vaccines: mutated p21 ras oncogene as a model.

Kubuschok B, Cochlovius C, Jung W, Schmits R, Trümper L, Hartmann F, Renner C, Pfreundschuh M.

Cancer Gene Ther. 2000 Sep;7(9):1231-40.

38.

[Isolated tumor cells in bone marrow predicts reduced survival in lymph node-negative non-small-cell lung cancer].

Passlick B, Kubuschok B, Izbicki JR, Thetter O, Pantel K.

Pneumologie. 2000 Aug;54(8):355-60. German.

PMID:
11008478
39.

Isolated tumor cells in bone marrow predict reduced survival in node-negative non-small cell lung cancer.

Passlick B, Kubuschok B, Izbicki JR, Thetter O, Pantel K.

Ann Thorac Surg. 1999 Dec;68(6):2053-8.

PMID:
10616976
40.

Myasthenia gravis: selective enrichment of antiacetylcholine receptor antibody production in untransformed human B cell cultures.

Padberg F, Matsuda M, Fenk R, Patenge N, Kubuschok B, Hohlfeld R, Wekerle H, Spuler S.

Eur J Immunol. 1999 Nov;29(11):3538-48.

41.

Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non-small-cell lung cancer.

Kubuschok B, Passlick B, Izbicki JR, Thetter O, Pantel K.

J Clin Oncol. 1999 Jan;17(1):19-24.

PMID:
10458213
42.

Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis.

Weber F, Polak T, Günther A, Kubuschok B, Janovskaja J, Bitsch A, Poser S, Rieckmann P.

Ann Neurol. 1998 Jul;44(1):27-34.

PMID:
9667590
43.

Serum levels of macrophage-derived protein MRP-8/14 are elevated in active multiple sclerosis.

Bogumil T, Rieckmann P, Kubuschok B, Felgenhauer K, Brück W.

Neurosci Lett. 1998 May 15;247(2-3):195-7.

PMID:
9655626
44.

Expression of MHC molecules and ICAM-1 on non-small cell lung carcinomas: association with early lymphatic spread of tumour cells.

Passlick B, Pantel K, Kubuschok B, Angstwurm M, Neher A, Thetter O, Schweiberer L, Izbicki JR.

Eur J Cancer. 1996 Jan;32A(1):141-5.

PMID:
8695222
45.

Detection of disseminated lung cancer cells in lymph nodes: impact on staging and prognosis.

Passlick B, Izbicki JR, Kubuschok B, Thetter O, Pantel K.

Ann Thorac Surg. 1996 Jan;61(1):177-82; discussion 183.

PMID:
8561549
46.

[The significance of regional lymphatic tumor cell dissemination in patients with resectable non-small cell bronchial carcinoma. Results of a prospective study].

Passlick B, Thetter O, Pantel K, Kubuschok B, Pichlmeier U, Schweiberer L, Izbicki JR.

Chirurg. 1995 Aug;66(8):780-5; discussion 785-6. German.

PMID:
7587541
47.

Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer.

Passlick B, Izbicki JR, Kubuschok B, Nathrath W, Thetter O, Pichlmeier U, Schweiberer L, Riethmüller G, Pantel K.

J Clin Oncol. 1994 Sep;12(9):1827-32.

PMID:
8083707
48.

Radical systematic mediastinal lymphadenectomy in non-small cell lung cancer: a randomized controlled trial.

Izbicki JR, Thetter O, Habekost M, Karg O, Passlick B, Kubuschok B, Busch C, Haeussinger K, Knoefel WT, Pantel K, et al.

Br J Surg. 1994 Feb;81(2):229-35.

PMID:
8156344
49.

Expression of major histocompatibility class I and class II antigens and intercellular adhesion molecule-1 on operable non-small cell lung carcinomas: frequency and prognostic significance.

Passlick B, Izbicki JR, Simmel S, Kubuschok B, Karg O, Habekost M, Thetter O, Schweiberer L, Pantel K.

Eur J Cancer. 1994;30A(3):376-81.

PMID:
8204362

Supplemental Content

Loading ...
Support Center